# Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

> **NCT06677060** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 11300 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Baxdrostat and dapagliflozin
- **OTHER:** Placebo and dapagliflozin

## Key facts

- **NCT ID:** NCT06677060
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-14
- **Primary completion:** 2029-12-17
- **Final completion:** 2029-12-17
- **Target enrollment:** 11300 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06677060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06677060, "Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT06677060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*